A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Eligible for screening study DCP 001
S1914 is closed to accrual, effective September 6, 2024